Most importantly, human malignant glioma cells were engineered to release high amounts of Decoy receptor 3 (DcR3), which is overexpressed in the lungs and gastrointestinal tract [3, 4] and is associated with DcR3 binding to the fatty acid synthetase ligand (FasL) and inhibition of FasL-induced apoptosis [5]. This evidence concerns the gene FASLG and malignant glioma.